The short version of prohibited list fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-09 and is reviewed periodically as new material appears.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
According to the BPC: "...the plan would enact tax reform by lowering both the corporate and individual income tax rates and raising revenue by broadening the base. Policies are endorsed that improve the health of the Social Security program, restrain health care cost growth, control annually appropriated spending, and make cuts to other entitlement programs." The plan proposes to raise approximately $1 trillion less revenue over the 2013–2022 decade than the Simpson-Bowles and Domenici-Rivlin plans, while cutting non-defense discretionary spending more deeply and reducing the defense spending cuts mandated in the Budget Control Act of 2011. According to the Center on Budget and Policy Priorities, this plan is ideologically to the Right of either the Simpson-Bowles or Domenici-Rivlin plans. In May 2012, House Republicans put forward five separate budget proposals for a vote in the Senate. The Republican proposals included the House-approved proposal by House Budget Chairman Paul Ryan and one that was very close in content to the budget proposal submitted earlier in 2012 by President Barack Obama. The other three proposals each called for greatly reduced government spending. The budget put forward by Senator Mike Lee would halve the government over the next 25 years. Senator Rand Paul's budget included proposed cuts to Medicare, Social Security benefits and the closure of four Cabinet departments. The budget plan from Senator Patrick Toomey aimed to balance the budget within eight years. All five of the proposed plans were rejected in the Senate.
The lawsuit continued to the Supreme Court after Schmitt left the office of attorney general. In Biden v. Nebraska, the Court held that the United States Secretary of Education lacked the authority to waive student loans.
He sailed for New York on the RMS Caronia on 19 September 1925, intending to study under Robert Chambers at Cornell University Medical College, but the micromanipulator he required for his research on the blood vessels of the brain was not available, so he arranged to work at the laboratory of Alfred Newton Richards at the University of Pennsylvania. He finally joined Chambers in March 1926. He hoped to be able to return to the UK via Australia and marry Ethel Reed in Adelaide, but in November 1925 he accepted an offer of a research position at London Hospital. The position came with five years' tenure and a salary of £850 per annum (equivalent to £45,000 in 2025), but they wanted him to start immediately. Florey managed to negotiate a delay, but only until May 1926. He returned to the UK on 13 May. Ethel joined him there in September, and they were married at Holy Trinity, Paddington, on 19 October.
In industrial anaerobic digestion processes, such as wastewater treatment or the digestion of organic waste from agriculture, hydrogen sulfide can be formed from the reduction of sulfate and the degradation of amino acids and proteins within organic compounds. Sulfates are relatively non-inhibitory to methane forming bacteria but can be reduced to H2S by sulfate reducing bacteria, of which there are several genera.
== Research == Although opioids are typically first-line treatments in severe pain, several trials suggest that methocarbamol may improve recovery and decrease hospital length of stay in those with muscle spasms associated with rib fractures. However, methocarbamol was less useful in the treatment of acute traumatic pain in general. Long-term studies evaluating the risk of development of cancer in using methocarbamol have not been performed. There are currently no studies evaluating the effect of methocarbamol on mutagenesis or fertility. The safety and efficacy of methocarbamol have not been established in pediatric individuals below the age of 16 except in tetanus.
Sources: en.wikipedia.org
==== Metabolism ==== Scientists performed a study on NM-2-AI metabolism in silico and in vivo, in order to identify the main metabolites to be screened in the different biological samples. They performed the in silico metabolism prediction of NM-2-AI using MetaSiteTM software and subsequently verified the presence of metabolites in the blood, urine and hair of mice after NM-2-AI administration. LC-HRMS analysis identified seven main metabolites in the urine. They were identified, by their accurate masses and fragmentation patterns, as 2-aminoindane (2AI), two hydroxy-2-AI and four hydroxy-NM-2-AI; one of the hydroxy-NM-2-AI and one of the hydroxy-2-AI underwent also to conjugation. NM-2-AI and 2-AI were also detected by LC-HRMS in the hair and blood
== Chemistry == Etilefrine, also known as 3,β-dihydroxy-N-ethylphenethylamine, is a substituted phenethylamine derivative. It is an analogue of epinephrine (3,4,β-trihydroxy-N-methylphenethylamine), of phenylephrine ((R)-β,3-dihydroxy-N-methylphenethylamine), of metaterol (3,β-dihydroxy-N-isopropylphenethylamine), and of norfenefrine (3,β-dihydroxyphenethylamine), as well as of metaraminol ((1R,2S)-3,β-dihydroxy-α-methylphenethylamine). Etilefrine pivalate (K-30052) is the 3-pivalyl ester of etilefrine. In contrast to etilefrine, etilefrine pivalate was never marketed.
The picture is elaborately framed by five successive decorative borders with naturalistic vine rinceau, suggestive of Roman art. The colors of the murals are various shades of brown, with smatterings of light green, but no blue, defining the so-called "orange and green" style. The center of the ceiling has motifs of the sun and moon, two monks, and a bird flying with a human figure in its claws. The sides of the ceiling are composed of diamond-shaped mountains, around which are naturalistic motifs of humans, animals, lakes and trees, a possibly Near-Eastern design which was generally adopted in later caves at Kizil. A band of fantastic animals separated the ceiling from the side walls. The general style appears to be early, and possibly derived from Kashmir and Cave 24 at Bamiyan. The lunettes bordering the ceiling display ornate Buddhist scenes. The right lunette is difficult to identify, but seems to represent a king or a Bodhisattava bending towards a warrior figure. The bottom portion shows a palatial scene, with a figure on a couch surrounded by devatas. The left lunette shows the Buddha of the future Maitreya in the Tusita Heaven. Below this is a depiction of Mount Sumeru surrounding by various Nagas, figures of devotees, and animals. Small figures of kneeling devotees in tunics, about 40 centimeters (15 inches) tall, some armed with a dagger, appear next to the left and right corners of the back-wall mural: probably noble and wealthy Kuchean donors of the 4th century CE. One of the donors holds three burning incense cones.
The suit contains an on-board computer system that constantly monitors the user's health and vital signs, and reacts to any changes in the user's condition. It also projects a heads-up display (HUD) which displays Gordon's health and suit charge level, remaining ammunition, and a crosshair. As a means of immersing the player in the role, Gordon never speaks, and there are no cutscenes or mission briefings—all action is viewed through Gordon's eyes, with the player retaining control of Gordon's actions at nearly all times. Gordon does not appear to wear the helmet, although other dead scientists that appear throughout the game have one. The images of Gordon are only seen on the game's cover and menu pages, and also in advertisements, making them marketing tools rather than pictures of what Gordon is "really like". Gabe Newell has stated that Valve sees no reason to give Gordon a voice. In Half-Life, Gordon wears the Mark IV suit. Later in the game, the suit is equipped with an optional long-jump module so Gordon can leap great distances. It is charged using power modules throughout Black Mesa. In Half-Life 2 Gordon receives the upgraded Mark V suit, which lacks the long-jump module but gains several new abilities. It features a visual zooming capability, limited sprinting, an anti-venom injector, an optional ammo and a health counter on the crosshair, and has been modified to use Combine power nodes to charge the suit.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.